依普黄酮治疗骨质疏松症。 - Suppr

Suppr

超能文献

Ipriflavone for the treatment of osteoporosis.

作者信息

Choi Y K, Han I K, Yoon H K

机构信息

Kyung-Hee University School of Medicine, Department of Internal Medicine, Seoul, Korea.

出版信息

Osteoporos Int. 1997;7 Suppl 3:S174-8. doi: 10.1007/BF03194367.

DOI:10.1007/BF03194367

PMID:9536327

Abstract

摘要

相似文献

Ipriflavone for the treatment of osteoporosis.依普黄酮治疗骨质疏松症。

Osteoporos Int. 1997;7 Suppl 3:S174-8. doi: 10.1007/BF03194367.

Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.依普黄酮给药对去卵巢女性骨量和代谢的影响。

J Endocrinol Invest. 1993 May;16(5):333-7. doi: 10.1007/BF03348848.

Ipriflavone: background.依普黄酮：背景

Calcif Tissue Int. 1997;61 Suppl 1:S3-4.

The future of ipriflavone in the management of osteoporotic syndromes.依普黄酮在骨质疏松综合征管理中的未来。

Calcif Tissue Int. 1997;61 Suppl 1:S33-5. doi: 10.1007/s002239900383.

Effect of ipriflavone--a synthetic derivative of natural isoflavones--on bone mass loss in the early years after menopause.依普黄酮（一种天然异黄酮的合成衍生物）对绝经后早期骨质流失的影响。

Menopause. 1998 Spring;5(1):9-15.

Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.异黄酮长期治疗对低骨量绝经后妇女的影响。

Calcif Tissue Int. 1997;61 Suppl 1:S19-22. doi: 10.1007/s002239900380.

Ipriflavone and low doses of estrogens in the prevention of bone mineral loss in climacterium.依普黄酮与低剂量雌激素对更年期妇女骨矿物质流失的预防作用

Bone Miner. 1992 Oct;19 Suppl 1:S49-56. doi: 10.1016/0169-6009(92)90866-c.

Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2-year follow-up study.罗格列酮对绝经后糖尿病女性骨密度和重塑参数的影响：一项为期 2 年的随访研究。

Clin Endocrinol (Oxf). 2010 Sep;73(3):305-12. doi: 10.1111/j.1365-2265.2010.03784.x. Epub 2010 Feb 10.

Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women.低剂量异黄酮衍生物依普黄酮与雌激素替代疗法联合应用对绝经后女性骨密度及骨代谢的影响

Maturitas. 1997 Sep;28(1):75-81. doi: 10.1016/s0378-5122(97)00059-5.

Ipriflavone: an important bone-building isoflavone.依普黄酮：一种重要的骨生成异黄酮。

Altern Med Rev. 1999 Feb;4(1):10-22.

引用本文的文献

Osteoporosis Update 1997. Symposium proceedings. Osaka, Japan, 13-16 November 1997.《1997年骨质疏松症最新进展》。研讨会论文集。日本大阪，1997年11月13日至16日。

Osteoporos Int. 1997;7 Suppl 3:1-222.

本文引用的文献

Protein measurement with the Folin phenol reagent.使用福林酚试剂进行蛋白质测定。

J Biol Chem. 1951 Nov;193(1):265-75.

Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis.异丙黄酮和鲑鱼降钙素治疗绝经后骨质疏松症后的代谢及骨骼效应

Biomed Pharmacother. 1995;49(10):465-8. doi: 10.1016/0753-3322(96)82691-6.

[Pharmacokinetics of ipriflavone].[依普黄酮的药代动力学]

Acta Pharm Hung. 1995 Nov;65(6):219-22.

Effects of ipriflavone and its metabolites on human articular chondrocytes cultivated in clusters.

Osteoarthritis Cartilage. 1996 Mar;4(1):1-8. doi: 10.1016/s1063-4584(96)80002-1.

Potential mechanism of estrogen-mediated decrease in bone formation: estrogen increases production of inhibitory insulin-like growth factor-binding protein-4.雌激素介导的骨形成减少的潜在机制：雌激素增加抑制性胰岛素样生长因子结合蛋白-4的产生。

Proc Assoc Am Physicians. 1996 Mar;108(2):155-64.

Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone.使用低剂量结合雌激素和非激素骨活性药物依普黄酮预防绝经后早期骨质流失。

Osteoporos Int. 1995;5(6):462-6. doi: 10.1007/BF01626609.

Osteoporosis.骨质疏松症

Br J Rheumatol. 1993 Jun;32 Suppl 4:48-55. doi: 10.1093/rheumatology/32.suppl_4.48.

Mortality and morbidity after hip fractures.髋部骨折后的死亡率和发病率。

BMJ. 1993 Nov 13;307(6914):1248-50. doi: 10.1136/bmj.307.6914.1248.

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.用于预测髋部骨折的不同部位骨密度。骨质疏松性骨折研究组。

Lancet. 1993 Jan 9;341(8837):72-5. doi: 10.1016/0140-6736(93)92555-8.

Update on continuous estrogen-progestin replacement therapy.连续雌激素-孕激素替代疗法的最新进展。

Am Fam Physician. 1994 Nov 15;50(7):1519-23, 1527-8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验